SOURCE: CONMED Corporation

CONMED Corporation

July 26, 2012 07:00 ET

CONMED Corporation Announces Second Quarter 2012 Financial Results

Conference Call to Be Held at 10:00 a.m. ET Today

UTICA, NY--(Marketwire - Jul 26, 2012) - CONMED Corporation (NASDAQ: CNMD)

  • Sales Increase 3.5%
  • GAAP EPS Increases 20%
  • Adjusted EPS Increases 23% 

CONMED Corporation (NASDAQ: CNMD) today announced financial results for the second quarter ended June 30, 2012.

"CONMED delivered strong earnings and generated solid cash flow during the second quarter," commented Mr. Joseph J. Corasanti, President and CEO. "Earnings per share grew 20% and adjusted earnings per share increased 23% on overall sales growth of 3.5%. Single-use products continued their momentum from the first quarter, achieving overall revenue growth of 7.5%. Moreover, we continue to improve our operating and EBITDA margin metrics."

As discussed below under "Use of Non-GAAP Financial Measures," the Company presents various non-GAAP adjusted financial measures in this release. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with generally accepted accounting principles ("GAAP"). Please refer to the attached reconciliation between GAAP and adjusted financial measures.

Second Quarter 2012 Financial Highlights:

  • Sales grew to $189.7 million, an increase of 3.5% (organic decline of 0.4%).

  • Single-use products comprised 81.1% of total revenues and grew 7.5%, while sales of capital products declined 10.7%.

  • Diluted earnings per share (GAAP) grew 20.0% to $0.36.

  • Adjusted diluted earnings per share grew 22.9% to $0.43.

  • Adjusted operating margin expanded 90 basis points to 10.6%.

  • GAAP operating margin was 9.0%.

  • Adjusted EBITDA margin expanded 160 basis points to 16.4%.

  • GAAP EBITDA margin operating margin was 14.8%.

  • The Board of Directors continued the cash dividend policy and declared the second quarterly dividend of $0.15 per share, which was paid on July 6, 2012.

Six Months 2012 Financial Highlights

  • Sales grew to $384.0 million, an increase of 4.7% (increase of 0.7% organic).

  • Single-use products comprised 80.3% of total revenues and grew 8.3%, while capital products declined 7.6%.

  • Diluted earnings per share (GAAP) grew 16.4% to $0.71.

  • Adjusted earnings per share grew 18.1% to $0.85.

  • Adjusted operating margin expanded 60 basis points to 10.6%.

  • GAAP operating margin was 8.9%.

  • Adjusted EBITDA margin expanded 160 basis points to 16.5%.

  • GAAP EBITDA margin was 14.8%.

International sales in the second quarter and first half of 2012 were $96.4 million and $194.6 million, respectively, slightly more than 50.0% of total sales. The recent volatility in foreign currency exchange rates was mitigated by the Company's currency hedging. Net of the hedges, foreign currency exchange rates were approximately the same in 2012 as those of 2011. 

Cash provided by operating activities in the second quarter of 2012 increased from the prior year period and amounted to $25.6 million. For the six months ended June 2012, cash provided by operating activities totaled $33.3 million. As previously disclosed, cash flow in the first quarter of 2012 was affected by a contribution of $6.5 million to the Company's frozen pension plan and payment of incentive compensation.

Outlook

"CONMED has demonstrated superior earnings and cash flow in the first half of 2012 and we expect to continue these trends in the second half of the year," continued Mr. Corasanti. "Therefore, we are reiterating the previously provided full year 2012 earnings guidance of adjusted earnings per share of $1.75 - $1.85. As to the top-line, while single-use product sales continue to be strong, capital product sales in the first half of 2012 were lower than anticipated due to lingering global economic headwinds. Accordingly, the sales forecast for 2012 has been revised to $765 - $775 million from $775 - $785 million." 

"For the third quarter of 2012, we anticipate sales will approximate $180 - $185 million and adjusted earnings per share are forecasted to be $0.38 - $0.42," noted Mr. Corasanti.

The sales and earnings forecasts have been developed using June 2012 currency exchange rates and take into account the currency hedges entered into by the Company. CONMED estimates that 80% of the currency exposure is hedged for 2012 at the following average annual exchange rates: Euro - $1.41, CAD - $1.00, GPB - $1.60 and AUD - $1.00. 

The adjusted estimates for the second quarter and full year 2012 exclude unusual matters, such as the manufacturing restructuring costs expected to be incurred in 2012 due to the relocation of manufacturing activities from the Santa Barbara, California site to the Company's facilities in Chihuahua, Mexico and Largo, Florida. Marketing and R&D activities will remain in Santa Barbara, as previously disclosed. Additionally, the Company has announced the consolidation of the Tampere, Finland location into United States facilities. The consolidation will occur over the next twelve months and costs related to this consolidation are excluded from the estimates above.

Association with The Musculoskeletal Transplant Foundation

On January 3, 2012, CONMED became the exclusive world-wide marketing representative of MTF's sports medicine allograft tissues. In accordance with MTF's commitment to the stewardship of the donated gift, the organization maintains full responsibility for all activities related to donor suitability, quality acceptance, processing, storage, and distribution of the tissue, as well as reimbursement of service fees related to the sports medicine allografts. CONMED's team of surgical representatives serves as the educational resource to surgeons and facilities concerning the suitability of MTF allografts for ligament reconstruction, cartilage repair and meniscal transplantation, as well as for biologic solutions, including scaffolds and fixation devices. MTF will share 50% of the service revenue with CONMED for these educational activities.

Upon signing of the agreement, CONMED paid $63 million to MTF. The agreement calls for additional consideration to be paid to MTF of $84 million over the next four years contingent upon MTF providing an adequate supply of tissue. We have recorded the full amount of the consideration as a long term asset and amortize this amount ratably over the 25 year life of the agreement. Remaining contingent payments to MTF have been recorded as other liabilities. Revenues from the MTF association amounted to $7.2 million in the second quarter of 2012 and $14.7 million for the first six month of 2012.

Unusual charges

During the first half of 2012, the Company continued the on-going consolidation of certain administrative functions and the transfer of additional product lines to its Mexican manufacturing facility and began the consolidation of the Tampere facility. Also incurred were integration costs relative to the purchase of a distributor in northern Europe and litigation costs associated with a contractual dispute with a former distributor. Expenses associated with these activities, including severance and relocation costs, amounted to $1.9 million, net of tax, in the second quarter of 2012 and $4.1 million net of tax for the six months. These charges are included in the GAAP earnings per share set forth above and are excluded from the adjusted results. For the remainder of 2012, the Company presently anticipates incurring additional pre-tax restructuring costs of $5.0 - $6.0 million on projects currently in process.

Use of non-GAAP financial measures

Management has disclosed adjusted financial measurements in this press announcement that present financial information that is not in accordance with generally accepted accounting principles. These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company's on-going financial performance from quarter-to-quarter and year-to-year on a regular basis, and for benchmarking against other medical technology companies. Adjusted net income and adjusted earnings per share measure the income of the Company excluding unusual credits or charges that are considered by management to be outside of the normal on-going operations of the Company. Management uses and presents adjusted net income and adjusted earnings per share because management believes that in order to properly understand the Company's short and long-term financial trends, the impact of unusual items should be eliminated from on-going operating activities. These adjustments for unusual items are derived from facts and circumstances that vary in frequency and impact on the Company's results of operations. Management uses adjusted net income and adjusted earnings per share to forecast and evaluate the operational performance of the Company as well as to compare results of current periods to prior periods on a consistent basis. Adjusted financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP. 

Conference call

The Company will webcast its second quarter 2012 conference call live over the Internet at 10:00 a.m. Eastern Time on Thursday, July 26, 2012. This webcast can be accessed from CONMED's web site at www.conmed.com. Replays of the call will be made available through August 5, 2012.

CONMED profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company's products serve the clinical areas of arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. They are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company's 3,400 employees distribute its products worldwide from several manufacturing locations.

Forward Looking Information

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw materials or transportation (viii) the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues; and/or (ix) the Company's ability to devise and execute strategies to respond to market conditions.

   
CONMED CORPORATION  
CONSOLIDATED STATEMENTS OF INCOME  
(in thousands except per share amounts)  
(unaudited)  
   
    Three months ended     Six months ended  
    June 30,     June 30,  
    2011     2012     2011     2012  
                                 
Net sales   $ 183,236     $ 189,695     $ 366,686     $ 384,011  
                                 
Cost of sales     90,795       88,761       177,775       180,692  
Cost of sales, other - Note A     986       1,202       1,740       2,676  
                                 
Gross profit     91,455       99,732       187,171       200,643  
                                 
Selling and administrative     67,862       73,707       137,940       148,513  
Research and development     6,797       7,192       14,478       14,287  
Other expense- Note B     98       1,775       792       3,763  
      74,757       82,674       153,210       166,563  
                                 
Income from operations     16,698       17,058       33,961       34,080  
                                 
Amortization of debt discount     1,113       -       2,207       -  
                                 
Interest expense     1,707       1,551       3,512       2,988  
                                 
Income before income taxes     13,878       15,507       28,242       31,092  
                                 
Provision for income taxes     5,198       5,211       10,567       10,828  
                                 
Net income   $ 8,680     $ 10,296     $ 17,675     $ 20,264  
                                 
Per share data:                                
                                 
  Net Income                                
    Basic   $ .31     $ .36     $ .62     $ .72  
    Diluted     .30       .36       .61       .71  
                                   
  Weighted average common shares                                
    Basic     28,448       28,327       28,356       28,178  
    Diluted     28,883       28,672       28,820       28,577  
                                     

Note A - Included in cost of sales, other in the three and six months ended June 30, 2011 are $1.0 million and $1.7 million, respectively, related to the consolidation of our production facilities. For the three and six months ending June 30, 2012, we incurred $1.2 million and $2.7 million, respectively, related to the consolidation of our production facilities.         

Note B - Included in other expense in the three and six months ended June 30, 2011 are $0.1 million and $0.8 million, respectively, related to consolidating certain administrative functions at our Utica, New York facility. For the three and six months ending June 30, 2012, we incurred $1.2 million and $1.5 million, respectively, related to administrative consolidation expense. Also included in other expense in the three and six months ending June 30, 2012 are $0.5 million and $1.6 million, respectively, in legal costs associated with a contractual dispute with a former distributor. Included in the six months ending June 30, 2012 is $0.7 million in costs associated with the acquisition of our former distributor in the Nordic region of Europe.

   
   
   
CONMED CORPORATION  
CONSOLIDATED CONDENSED BALANCE SHEETS  
(in thousands)  
(unaudited)  
ASSETS  
             
    December 31,     June 30,  
    2011     2012  
Current assets:                
  Cash and cash equivalents   $ 26,048     $ 16,246  
  Accounts receivable, net     135,641       136,095  
  Inventories     168,438       159,151  
  Deferred income taxes     10,283       10,906  
  Other current assets     16,314       15,037  
    Total current assets     356,724       337,435  
                 
Property, plant and equipment, net     139,187       140,844  
Deferred income taxes     2,389       2,443  
Goodwill     234,815       234,839  
Other intangible assets, net     195,531       191,741  
Other assets     6,948       153,929  
    Total assets   $ 935,594     $ 1,061,231  
                 
LIABILITIES AND SHAREHOLDERS' EQUITY                
                 
Current liabilities:                
  Current portion of long-term debt   $ 54,557     $ 22,534  
  Other current liabilities     76,627       112,713  
    Total current liabilities     131,184       135,247  
                   
Long-term debt     88,952       145,437  
Deferred income taxes     92,785       99,417  
Other long-term liabilities     49,602       87,747  
    Total liabilities     362,523       467,848  
                   
Shareholders' equity:                
  Capital accounts     244,980       255,044  
  Retained earnings     354,439       366,219  
  Accumulated other comprehensive loss     (26,348 )     (27,880 )
    Total shareholders' equity     573,071       593,383  
                   
    Total liabilities and shareholders' equity   $ 935,594     $ 1,061,231  
                 
                 
                 
CONMED CORPORATION  
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS  
(in thousands)  
(unaudited)  
   
    Six months ended  
    June 30,  
    2011     2012  
Cash flows from operating activities:                
  Net income   $ 17,675     $ 20,264  
  Adjustments to reconcile net income to net cash provided by operating activities:                
    Depreciation and amortization     21,047       23,064  
    Stock-based compensation expense     2,232       2,574  
    Deferred income taxes     8,981       6,091  
    Increase (decrease) in cash flows from changes in assets and liabilities:                
      Accounts receivable     (4,541 )     (1,027 )
      Inventories     78       3,078  
      Accounts payable     2,309       1,345  
      Income taxes payable     143       (4,589 )
      Accrued compensation and benefits     (5,684 )     (6,730 )
      Other assets     (2,226 )     (1,779 )
      Other liabilities     209       (9,014 )
  Net cash provided by operating activities     40,223       33,277  
                 
Cash flows from investing activities:                
      Purchases of property, plant, and equipment     (8,576 )     (11,596 )
      Payments related to business acquisitions and distribution agreement     (72 )     (64,116 )
  Net cash used in investing activities     (8,648 )     (75,712 )
                 
Cash flows from financing activities:                
      Payments on debt     (23,113 )     (32,538 )
      Proceeds from debt     -       57,000  
      Dividend payments from common stock     -       (4,328 )
      Net proceeds from common stock issued under employee plans     5,495       7,868  
      Other, net     (3,148 )     4,925  
  Net cash provided by (used in) financing activities     (20,766 )     32,927  
                 
Effect of exchange rate change on cash and cash equivalents     1,105       (294 )
                 
Net increase (decrease) in cash and cash equivalents     11,914       (9,802 )
                 
Cash and cash equivalents at beginning of period     12,417       26,048  
                 
Cash and cash equivalents at end of period   $ 24,331     $ 16,246  
                 
                 
                 
CONMED CORPORATION  
RECONCILIATION OF REPORTED NET INCOME TO NON-GAAP NET INCOME  
BEFORE UNUSUAL ITEMS AND AMORTIZATION OF DEBT DISCOUNT  
Three Months Ended June 30, 2011 and 2012  
(in thousands except per share amounts)  
(unaudited)  
             
    2011     2012  
                 
Reported net income   $ 8,680     $ 10,296  
                 
Facility consolidation costs included in cost of sales     986       1,202  
                 
Administrative consolidation costs included in other expense     98       1,231  
                 
Legal costs included in other expense     -       544  
                 
  Total other expense     98       1,775  
                 
Amortization of debt discount     1,113       -  
                 
Unusual expense before income taxes     2,197       2,977  
                 
Provision (benefit) for income taxes on unusual expenses     (801 )     (1,072 )
                 
Net income before unusual items and amortization of debt discount   $ 10,076     $ 12,201  
                 
Per share data:                
                 
Reported net income                
  Basic   $ 0.31     $ 0.36  
  Diluted     0.30       0.36  
                 
Net income before unusual items and amortization of debt discount                
  Basic   $ 0.35     $ 0.43  
  Diluted     0.35       0.43  
                   

Management has provided the above reconciliation of net income before unusual items and amortization of debt discount as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section "Use of Non-GAAP Financial Measures" above. We have included the amortization of debt discount in our analysis in order to facilitate comparison with the non-GAAP earnings guidance provided in the "Outlook" section of this and previous releases which exclude such expense.

   
   
   
CONMED CORPORATION  
RECONCILIATION OF REPORTED NET INCOME TO NON-GAAP NET INCOME  
BEFORE UNUSUAL ITEMS AND AMORTIZATION OF DEBT DISCOUNT  
Six Months Ended June 30, 2011 and 2012  
(in thousands except per share amounts)  
(unaudited)  
             
    2011     2012  
                 
Reported net income   $ 17,675     $ 20,264  
                 
Facility consolidation costs included in cost of sales     1,740       2,676  
                 
Administrative consolidation costs included in other expense     792       1,504  
                 
Costs associated with purchase of Nordic region distributor     -       704  
                 
Legal costs included in other expense     -       1,555  
                 
    Total other expense     792       3,763  
                 
Amortization of debt discount     2,207       -  
                 
Unusual expense before income taxes     4,739       6,439  
                 
Provision (benefit) for income taxes on unusual expenses     (1,727 )     (2,318 )
                 
Net income before unusual items and amortization of debt discount   $ 20,687     $ 24,385  
                 
Per share data:                
                 
Reported net income                
  Basic   $ 0.62     $ 0.72  
  Diluted     0.61       0.71  
                 
Net income before unusual items and amortization of debt discount                
  Basic   $ 0.73     $ 0.87  
  Diluted     0.72       0.85  
                 

Management has provided the above reconciliation of net income before unusual items and amortization of debt discount as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section "Use of Non-GAAP Financial Measures" above. We have included the amortization of debt discount in our analysis in order to facilitate comparison with the non-GAAP earnings guidance provided in the "Outlook" section of this and previous releases which exclude such expense.

   
   
   
CONMED CORPORATION  
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES  
(in thousands)  
(unaudited)  
                         
    Three months ended     Six months ended  
    June 30,     June 30,  
    2011     2012     2011     2012  
                                 
Reported income from operations   $ 16,698     $ 17,058     $ 33,961     $ 34,080  
                                 
Facility consolidation costs included in cost of sales     986       1,202       1,740       2,676  
                                 
Administrative consolidation costs included in other expense     98       1,231       792       1,504  
                                 
Costs associated with purchase of Nordic region distributor     -       -       -       704  
                                 
Legal costs included in other expense     -       544       -       1,555  
                                 
Adjusted income from operations   $ 17,782     $ 20,035     $ 36,493     $ 40,519  
                                 
Operating Margin                                
  Reported (GAAP)     9.1 %     9.0 %     9.3 %     8.9 %
                                 
  Adjusted (Non-GAAP)     9.7 %     10.6 %     10.0 %     10.6 %
                                 

Management has provided the above reconciliations as additional measures that investors can use to compare financial results between reporting periods. Management believes these reconciliations provide a useful presentation of financial measures as discussed in the section "Use of Non-GAAP Financial Measures" above.

   
   
   
CONMED CORPORATION  
RECONCILIATION OF REPORTED NET INCOME TO EBITDA & ADJUSTED EBITDA  
(in thousands)  
(unaudited)  
                         
    Three months ended     Six months ended  
    June 30,     June 30,  
    2011     2012     2011     2012  
                                 
Net Income   $ 8,680     $ 10,296     $ 17,675     $ 20,264  
                                 
Provision for income taxes     5,198       5,211       10,567       10,828  
                                 
Interest expense     1,707       1,551       3,512       2,988  
                                 
Depreciation     4,567       4,586       8,983       9,274  
                                 
Amortization of debt discount     1,113       -       2,207       -  
                                 
Amortization, all other     4,719       6,459       9,240       13,423  
                                 
EBITDA (using GAAP measures)   $ 25,984     $ 28,103     $ 52,184     $ 56,777  
                                 
Facility consolidation costs included in cost of sales     986       1,202       1,740       2,676  
                                 
Administrative consolidation costs included in other expense     98       1,231       792       1,504  
                                 
Costs associated with purchase of Nordic region distributor     -       -       -       704  
                                 
Legal costs included in other expense     -       544       -       1,555  
                                 
Adjusted EBITDA   $ 27,068     $ 31,080     $ 54,716     $ 63,216  
                                 
EBITDA Margin                                
  EBITDA (using GAAP measures)     14.2 %     14.8 %     14.2 %     14.8 %
                                   
  Adjusted EBITDA (using non-GAAP measures)     14.8 %     16.4 %     14.9 %     16.5 %
                                 

Management has provided the above reconciliations as additional measures that investors can use to compare financial results between reporting periods. Management believes these reconciliations provide a useful presentation of financial measures as discussed in the section "Use of Non-GAAP Financial Measures" above.

   
   
   
CONMED CORPORATION  
Second Quarter Sales Summary  
   
    Three Months Ended June 30,  
                         
                      Constant  
                      Currency  
    2011     2012     Growth     Growth  
    (in millions)              
Arthroscopy                            
  Single-use   $ 57.0     $ 67.5     18.4 %   18.6 %
  Capital     13.6       13.5     -0.7 %   0.0 %
      70.6       81.0     14.7 %   15.0 %
                             
Powered Surgical Instruments                            
  Single-use     19.8       20.9     5.6 %   5.9 %
  Capital     18.5       16.3     -11.9 %   -11.7 %
      38.3       37.2     -2.9 %   -2.6 %
                             
Electrosurgery                            
  Single-use     18.1       18.4     1.7 %   2.2 %
  Capital     8.0       6.0     -25.0 %   -25.0 %
      26.1       24.4     -6.5 %   -6.1 %
                             
Endoscopic Technologies                            
  Single-use     12.5       13.3     6.4 %   7.1 %
Endosurgery                            
  Single-use and reposable     19.1       18.2     -4.7 %   -4.7 %
Patient Care                            
  Single-use     16.6       15.6     -6.0 %   -6.6 %
                             
Total                            
  Single-use and reposable     143.1       153.9     7.5 %   7.8 %
  Capital     40.1       35.8     -10.7 %   -10.3 %
    $ 183.2     $ 189.7     3.5 %   3.8 %
                             
                             
                             
CONMED CORPORATION  
Six-Month Sales Summary  
   
    Six Months Ended June 30,  
                         
                      Constant  
                      Currency  
    2011     2012     Growth     Growth  
    (in millions)              
Arthroscopy                            
  Single-use   $ 115.1     $ 136.7     18.8 %   18.4 %
  Capital     30.9       30.5     -1.3 %   -1.0 %
      146.0       167.2     14.5 %   14.3 %
                             
Powered Surgical Instruments                            
  Single-use     40.2       42.4     5.5 %   5.4 %
  Capital     36.2       33.4     -7.7 %   -7.9 %
      76.4       75.8     -0.8 %   -0.9 %
                             
Electrosurgery                            
  Single-use     34.8       35.0     0.6 %   0.6 %
  Capital     14.9       11.9     -20.1 %   -20.1 %
      49.7       46.9     -5.6 %   -5.6 %
                             
Endoscopic Technologies                            
  Single-use     24.4       26.2     7.4 %   7.3 %
Endosurgery                            
  Single-use and reposable     37.0       36.3     -1.9 %   -1.9 %
Patient Care                            
  Single-use     33.2       31.6     -4.8 %   -5.1 %
                             
Total                            
  Single-use and reposable     284.7       308.2     8.3 %   8.1 %
  Capital     82.0       75.8     -7.6 %   -7.5 %
    $ 366.7     $ 384.0     4.7 %   4.6 %
                             
                             
                             

Contact Information

  • CONTACT:
    CONMED Corporation
    Robert Shallish
    Chief Financial Officer
    315-624-3206


    FTI Consulting
    Investors:
    Brian Ritchie
    212-850-5600